- Company
- Sales of AZ COVID vaccine increased 32% to 655.3 billion won
- by Apr 6, 2022 06:05am
- AstraZeneca Korea surpassed 600 billion won in sales last year by supplying the COVID-19 vaccine. According to an audit report by AstraZeneca Korea, the company recorded 655.3 billion won in sales last year. The figure is up 31.6 percent from the previous year's 498.1 billion won. Operating profit was 26 billion won, up 7.5% from 24.2 bill
- Company
- Sales of MSD in Korea exceeded 500 billion won
- by Apr 5, 2022 09:32am
- MSD Korea surpassed 500 billion won in sales last year. Keytruda's effect increased 1% year-on-year. Analysts say that it will be able to quickly recover its past sales of 800 billion won before Organon's spin-off. According to MSD audit report, the company recorded 541.9 billion won in sales last year. The figure is up 11.8% from the previous y
- Company
- Imbruvica fails CDDC twice and reattempts 1st-line reimb.
- by Eo, Yun-Ho Apr 5, 2022 05:59am
- Once again, the blood cancer drug ‘Imbruvica’ is attempting to expand reimbursement to first-line treatment. According to industry sources, Janssen Korea has applied for the reimbursement extension of its Imbruvica (ibrutinib) as a first-line treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) to once
- Company
- AZ starts next-gen ADC dev with confidence from Enhertu
- by Apr 4, 2022 06:07am
- AstraZeneca is leading the next-generation ADC development environment. The company, which has successfully commercialized ‘Enhertu’ in partnership with Daiichi Sankyo, is targeting areas slow in development such as triple-negative breast cancer. On the 31st, AstraZeneca received approval for its Phase III trial of a new ADC drug last
- Company
- Keytruda, the primary treatment for esophageal cancer
- by Apr 4, 2022 06:07am
- Keytruda, an immuno-cancer drug of MSD, has become the primary option in esophageal cancer, where treatments have been limited. The medical team predicted that an immuno-cancer drug-oriented treatment strategy using Keytruda or Opdivo will be established depending on the PD-L1 expression rate. At a seminar to commemorate the expansion of Keytrud
- Company
- Export of Celltrion/Samsung bioepis exceed ₩10trillion
- by Chon, Seung-Hyun Apr 3, 2022 04:18pm
- According to the Financial Supervisory Service on the 1st, four biosimilars, Celltrion Healthcare's Remsima, Truxima, Herzuma and Remsima SC, recorded a total of 1.5694 trillion won in exports last year. It fell 2.0% from 1.616 trillion won in 2020, but exceeded 1 trillion won for the third consecutive year from 2019. Celltrion Healthcare is an
- Company
- MS anticancer drug Revlimid, RVD combined therapy benefits
- by Nho, Byung Chul Apr 3, 2022 04:13pm
- BMS Pharmaceutical Korea announced on the 30th that Revlimid (Renalidomide) will be subject to benefits when administered in combination with Bortezomib/Dexamethasone, which is used to treat multiple myeloma patients, from the 1st of next month. The law has proven its superior effectiveness and tolerance compared to current standard treatm
- Company
- Revlimid's reimb extended…maintenance therapy remains
- by Eo, Yun-Ho Apr 1, 2022 06:04am
- The reimbursement standards for ‘Revlimid’ in combination with Velcade, and dexamethasone (RVD) for multiple myeloma have been extended. However, reimbursement for the drug as a maintenance therapy still remains unaddressed. Starting on April 1st, BMS Korea’s Revlimid (lenalidomide) will receive insurance benefits as part of RVd (lenal
- Company
- Roche joins in competition for RET-targeted therapies
- by Apr 1, 2022 06:03am
- Following Lilly, Roche has also received approval for its RET targeted anticancer therapy. The entrance of two drugs in a similar period is expected to spark new competition in the RET-targeted therapy market. On the 29th, Roche received marketing authorization for ‘Gavreto (pralsetinib) from the Ministry of Food and Drug Safety. Its fir
- Company
- Sandoz, launched a muscle relaxation antagonist with Ilsung
- by Mar 31, 2022 04:27pm
- Sandoz Korea announced on the 29th that it signed an exclusive sales partnership with Ilsung on the 28th with muscle relaxation antagonist Sandoz Sugammedex Sodium. According to the agreement, the two companies will start supplying and selling Sandoz Sugamadex on the 13th of next month. The two companies expected that Ilsung's sales know-how,
